INTELLIA THERAPEUTICS INC's ticker is NTLA and the CUSIP is 45826J105. A total of 168 filers reported holding INTELLIA THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is 0.67 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,572 | -19.8% | 49,727 | +3.4% | 0.00% | -33.3% |
| Q2 2023 | $1,961 | -8.5% | 48,088 | -16.4% | 0.00% | 0.0% |
| Q1 2023 | $2,143 | -7.6% | 57,490 | -13.5% | 0.00% | 0.0% |
| Q4 2022 | $2,320 | -99.9% | 66,498 | +12.4% | 0.00% | -40.0% |
| Q3 2022 | $3,312,000 | +7.2% | 59,178 | -0.9% | 0.01% | +25.0% |
| Q2 2022 | $3,090,000 | -22.8% | 59,704 | +8.3% | 0.00% | 0.0% |
| Q1 2022 | $4,005,000 | -40.6% | 55,113 | -3.3% | 0.00% | -42.9% |
| Q4 2021 | $6,737,000 | -17.3% | 56,981 | -6.1% | 0.01% | -22.2% |
| Q3 2021 | $8,143,000 | -25.2% | 60,699 | -9.7% | 0.01% | -18.2% |
| Q2 2021 | $10,885,000 | +136.1% | 67,229 | +17.0% | 0.01% | +120.0% |
| Q1 2021 | $4,610,000 | +54.0% | 57,440 | +4.4% | 0.01% | +66.7% |
| Q4 2020 | $2,994,000 | +227.6% | 55,040 | +19.7% | 0.00% | +200.0% |
| Q3 2020 | $914,000 | -5.5% | 45,990 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $967,000 | +91.5% | 45,990 | +11.4% | 0.00% | 0.0% |
| Q1 2020 | $505,000 | -18.3% | 41,290 | -2.0% | 0.00% | 0.0% |
| Q4 2019 | $618,000 | +9.8% | 42,140 | 0.0% | 0.00% | 0.0% |
| Q3 2019 | $563,000 | -17.0% | 42,140 | +1.8% | 0.00% | 0.0% |
| Q2 2019 | $678,000 | +13.0% | 41,390 | +17.8% | 0.00% | 0.0% |
| Q1 2019 | $600,000 | +24.2% | 35,140 | -0.7% | 0.00% | 0.0% |
| Q4 2018 | $483,000 | -59.3% | 35,390 | -14.7% | 0.00% | 0.0% |
| Q3 2018 | $1,187,000 | -0.3% | 41,490 | -4.7% | 0.00% | 0.0% |
| Q2 2018 | $1,191,000 | +117.3% | 43,540 | +67.5% | 0.00% | 0.0% |
| Q1 2018 | $548,000 | +23.7% | 25,990 | +12.8% | 0.00% | 0.0% |
| Q4 2017 | $443,000 | -50.3% | 23,040 | -35.7% | 0.00% | 0.0% |
| Q3 2017 | $891,000 | +268.2% | 35,848 | +137.4% | 0.00% | – |
| Q2 2017 | $242,000 | +139.6% | 15,100 | +109.7% | 0.00% | – |
| Q1 2017 | $101,000 | +7.4% | 7,201 | +0.0% | 0.00% | – |
| Q4 2016 | $94,000 | -23.6% | 7,200 | 0.0% | 0.00% | – |
| Q3 2016 | $123,000 | -20.1% | 7,200 | 0.0% | 0.00% | – |
| Q2 2016 | $154,000 | – | 7,200 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Discovery Value Fund | 561,561 | $17,756,559 | 9.73% |
| MPM BioImpact LLC | 544,639 | $17,221,485 | 4.60% |
| Casdin Capital, LLC | 1,178,075 | $37,250,732 | 4.12% |
| HIMENSION CAPITAL (SINGAPORE) PTE. LTD. | 1,145,091 | $36,207,777 | 3.72% |
| Atlas Venture Associates IX, LLC | 10,000 | $316,200 | 2.69% |
| Deep Track Capital, LP | 2,000,000 | $63,240,000 | 2.44% |
| ARK Investment Management | 9,948,629 | $314,575,638 | 2.41% |
| Merlin Capital, Inc | 18,526 | $585,792 | 2.19% |
| Orchard Capital Management, LLC | 159,155 | $5,032,481 | 1.86% |
| TANG CAPITAL MANAGEMENT LLC | 397,600 | $12,572,112 | 1.77% |